Apogenix is exploring partnerships with pharmaceutical and biotechnology companies as well as collaborations with leading academic institutions in order to advance the preclinical and clinical development and commercialization of its proprietary drug candidates targeting members of the TNF superfamily and TNF receptor superfamily. The TNF/TNF receptor superfamilies comprise more than a dozen proteins that play a crucial role in the regulation of the immune response, making them attractive immuno-oncology targets.
Our most advanced immuno-oncology candidate asunercept (APG101) is being developed for the treatment of solid tumors and malignant hematological diseases. It has delivered outstanding results in clinical trials in glioblastoma and myelodysplastic syndromes to date.
Apogenix’ proprietary HERA technology platform delivers single-chain fusion proteins which activate TNF superfamily receptors, thereby stimulating the anti-tumor immune response. Apogenix’ unique protein architecture offers clear advantages over other biologics such as antibodies and has the potential for broad application in oncology.
For more information regarding partnering opportunities, please contact:
Juergen Gamer, Ph.D.
VP Business Development
Phone: +49 (0) 6221 586080
Asunercept (APG101) – a CD95 ligand inhibitor – is currently being developed for the treatment of cancer and other malignant diseases. The excellent safety and tolerability of asunercept has been demonstrated in both animal models and clinical trials. Clinical trials in glioblastoma (GB) and myelodysplastic syndromes (MDS) have shown outstanding results.
With asunercept , Apogenix targets commercially attractive indications characterized by a high unmet medical need. GB and MDS, our initial target indications, are so-called orphan diseases with very few effective treatment options. Asunercept was granted orphan drug status for the treatment of glioma in the EU and for the treatment of GB and MDS in the US.
In a randomized controlled phase II trial in recurrent GB, treatment with asunercept in combination with radiotherapy has shown clinical
superiority in all study endpoints – progression-free survival, overall survival, and improvement in quality of life – compared to treatment with radiotherapy alone, demonstrating the efficacy of asunercept in the treatment of recurrent GB.
Final results of a phase I trial with asunercept for the treatment of MDS reveal an increase in erythrocyte precursor cells and a clear reduction of transfusion frequency in MDS patients, a clear indication of the efficacy of asunercept in the treatment of MDS.
The CD95 system, which is inhibited by asunercept, plays an important role in the progression of other solid tumors beyond GB, underlining the tremendous potential of asunercept in a broad range of oncology indications.
HERA Technology Platform
The Apogenix team has developed the unique, patent-protected HERA technology for the development of novel hexavalent receptor agonists that target different TNFSF-dependent signaling pathways, which play a crucial role in the regulation of the immune response. Apogenix’ novel TNF receptor agonists overcome the structural limitations of other biologics targeting TNFSF pathways, such as antibodies.
Through their unique molecular architecture, Apogenix’ single-chain fusion proteins combine high efficacy with defined, adjustable pharmacokinetics. These properties are especially important for activators of immune cells in order to stimulate an immune response against cancer cells.
Apogenix has successfully developed novel TRAIL receptor agonists based on this technology platform, which have demonstrated excellent anti-tumor efficacy in a large number of preclinical studies. The TRAIL receptor agonist program was successfully out-licensed to AbbVie in 2014. Other TNF receptor agonists including CD40, CD27, OX40, HVEM, GITR, and 4-1BB agonists are currently in preclinical development.